Trial Outcomes & Findings for Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT NCT03132532)

Last Updated: 2025-11-25

Results Overview

A Cox proportional hazards model stratified by stratification factors will be used to model PFS as a function of dose to test for an overall dose effect (a one-sided p-value \< 0.10 will be considered as significant evidence of a dose effect). Subsequently, separate Cox models stratified by stratification factors will compare PFS between 72 Gy and 60 Gy (for each, a one-sided p-value \< 0.10 will be considered as significant evidence of superiority). Kaplan Meier estimates and curves by dose level will also be generated

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

20 participants

Primary outcome timeframe

From randomization to the earliest date of documentation of disease progression or death due to any cause, assessed up to 5 years

Results posted on

2025-11-25

Participant Flow

Participant milestones

Participant milestones
Measure	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.\> \> Carboplatin: Chemotherapy\> \> Cisplatin: Chemotherapy\> \> Etoposide: Chemotherapy\> \> Paclitaxel: Chemotherapy\> \> Pemetrexed: Chemotherapy\> \> Proton Beam Radiation Therapy: Undergo PBT\> \> Quality-of-Life Assessment: Ancillary studies\> \> Questionnaire Administration: Ancillary studies	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.\> \> Carboplatin: Chemotherapy\> \> Paclitaxel: Chemotherapy\> \> Proton Beam Radiation Therapy: Undergo PBT\> \> Quality-of-Life Assessment: Ancillary studies\> \> Questionnaire Administration: Ancillary studies
Overall Study STARTED	10	10
Overall Study COMPLETED	10	7
Overall Study NOT COMPLETED	0	3

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

One patient on Arm C is missing ECOG data

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity.\> \> Carboplatin: Chemotherapy\> \> Cisplatin: Chemotherapy\> \> Etoposide: Chemotherapy\> \> Paclitaxel: Chemotherapy\> \> Pemetrexed: Chemotherapy\> \> Proton Beam Radiation Therapy: Undergo PBT\> \> Quality-of-Life Assessment: Ancillary studies\> \> Questionnaire Administration: Ancillary studies	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=7 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity.\> \> Carboplatin: Chemotherapy\> \> Paclitaxel: Chemotherapy\> \> Proton Beam Radiation Therapy: Undergo PBT\> \> Quality-of-Life Assessment: Ancillary studies\> \> Questionnaire Administration: Ancillary studies	Total n=17 Participants Total of all reporting groups
Age, Continuous	75.50 years n=10 Participants	74.0 years n=7 Participants	74.0 years n=17 Participants
Sex: Female, Male Female	6 Participants n=10 Participants	3 Participants n=7 Participants	9 Participants n=17 Participants
Sex: Female, Male Male	4 Participants n=10 Participants	4 Participants n=7 Participants	8 Participants n=17 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	9 Participants n=10 Participants	7 Participants n=7 Participants	16 Participants n=17 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1 Participants n=10 Participants	0 Participants n=7 Participants	1 Participants n=17 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Race (NIH/OMB) Asian	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Race (NIH/OMB) Black or African American	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Race (NIH/OMB) White	10 Participants n=10 Participants	7 Participants n=7 Participants	17 Participants n=17 Participants
Race (NIH/OMB) More than one race	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=10 Participants	0 Participants n=7 Participants	0 Participants n=17 Participants
Method of Payment MEDICARE	9 Participants n=10 Participants	5 Participants n=7 Participants	14 Participants n=17 Participants
Method of Payment MEDICARE AND PRIVATE INSURANCE	1 Participants n=10 Participants	0 Participants n=7 Participants	1 Participants n=17 Participants
Method of Payment PRIVATE INSURANCE	0 Participants n=10 Participants	2 Participants n=7 Participants	2 Participants n=17 Participants
Height (Cm)	167.100 cm STANDARD_DEVIATION 11.799 • n=10 Participants	171.714 cm STANDARD_DEVIATION 10.965 • n=7 Participants	169.000 cm STANDARD_DEVIATION 11.352 • n=17 Participants
Weight (Kg)	73.460 Kg STANDARD_DEVIATION 13.422 • n=10 Participants	84.900 Kg STANDARD_DEVIATION 18.190 • n=7 Participants	78.171 Kg STANDARD_DEVIATION 16.096 • n=17 Participants
Smoking Cessation Quit	8 Participants n=10 Participants	5 Participants n=7 Participants	13 Participants n=17 Participants
Smoking Cessation Kept smoking	2 Participants n=10 Participants	1 Participants n=7 Participants	3 Participants n=17 Participants
Smoking Cessation Non-smoker	0 Participants n=10 Participants	1 Participants n=7 Participants	1 Participants n=17 Participants
Baseline QOL 60	0 Participants n=10 Participants	1 Participants n=7 Participants	1 Participants n=17 Participants
Baseline QOL 70	0 Participants n=10 Participants	2 Participants n=7 Participants	2 Participants n=17 Participants
Baseline QOL 80	2 Participants n=10 Participants	0 Participants n=7 Participants	2 Participants n=17 Participants
Baseline QOL 90	5 Participants n=10 Participants	3 Participants n=7 Participants	8 Participants n=17 Participants
Baseline QOL 100	3 Participants n=10 Participants	1 Participants n=7 Participants	4 Participants n=17 Participants
ECOG Performance Status 0	3 Participants n=10 Participants • One patient on Arm C is missing ECOG data	3 Participants n=6 Participants • One patient on Arm C is missing ECOG data	6 Participants n=16 Participants • One patient on Arm C is missing ECOG data
ECOG Performance Status 1	7 Participants n=10 Participants • One patient on Arm C is missing ECOG data	3 Participants n=6 Participants • One patient on Arm C is missing ECOG data	10 Participants n=16 Participants • One patient on Arm C is missing ECOG data
Mayo prognostic score 32-37	0 Participants n=10 Participants	1 Participants n=7 Participants	1 Participants n=17 Participants
Mayo prognostic score 38-43	4 Participants n=10 Participants	3 Participants n=7 Participants	7 Participants n=17 Participants
Mayo prognostic score 44-47	4 Participants n=10 Participants	2 Participants n=7 Participants	6 Participants n=17 Participants
Mayo prognostic score 48-52	2 Participants n=10 Participants	1 Participants n=7 Participants	3 Participants n=17 Participants

PRIMARY outcome

Timeframe: From randomization to the earliest date of documentation of disease progression or death due to any cause, assessed up to 5 years

Outcome measures

Outcome measures
Measure	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=7 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Cisplatin: Chemotherapy \> \> Etoposide: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Pemetrexed: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies
Proportion of Participants With Progression Free Survival (PFS)	0.429 proportion of participants Interval 0.182 to 1.0	0.6 proportion of participants Interval 0.362 to 0.995

SECONDARY outcome

Timeframe: From randomization to death due to any cause, assessed up to 5 years

Will be modeled using Cox models. Kaplan-Meier estimates and curves by dose level will also be generated. OS will again be analyzed as exploratory analysis after 50 deaths per primary pairwise comparison have occurred or after all patients have completed follow-up (whichever occurs first).

Outcome measures

Outcome measures
Measure	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=7 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Cisplatin: Chemotherapy \> \> Etoposide: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Pemetrexed: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies
Overall Survival (OS) Alive	2 Participants	4 Participants
Overall Survival (OS) Dead	5 Participants	6 Participants

SECONDARY outcome

Timeframe: Up to 5 years

Graded by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Adverse events are graded on a scale of 0-5 with 5 being worst. The number of participants with Grade 2 or higher adverse events will be reported.

Outcome measures

Outcome measures
Measure	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=7 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Cisplatin: Chemotherapy \> \> Etoposide: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Pemetrexed: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies
Number of Participants With Adverse Events AE Grade 2+	6 Participants	9 Participants
Number of Participants With Adverse Events AE Grade 3+	5 Participants	6 Participants

SECONDARY outcome

Timeframe: Up to 5 years

Defined as the proportion of participants with documentation of local recurrence. The cumulative incidence of local failure will be estimated using Gray's methodology and compared across dose levels using Fine-Gray quadratic regression (with death as a competing risk).

Outcome measures

Outcome measures
Measure	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=7 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=8 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Cisplatin: Chemotherapy \> \> Etoposide: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Pemetrexed: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies
Proportion of Participants With Local-regional Failure	0.14 proportion of participants Interval 0.026 to 0.51	0.2 proportion of participants Interval 0.057 to 0.51

SECONDARY outcome

Timeframe: Up to 5 years

Defined as the proportion of participants with documentation of distant metastasis. The cumulative incidence of distant metastasis will be estimated using Gray's methodology and compared across dose levels using Fine-Gray quadratic regression (with death as a competing risk).

Outcome measures

Outcome measures
Measure	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=7 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo higher dose proton beam radiation therapy daily for a total of 72 Gy for up to 36 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 Participants Patients receive platinum based doublet chemotherapy consisting of low dose carboplatin and paclitaxel, standard etoposide cisplatin or carboplatin or standard pemetrexed with cisplatin or carboplatin weekly for up to 6 weeks at the discretion of the treating medical oncologist. Patients also undergo lower dose proton beam radiation therapy daily for a total of 60 Gy for up to 30 weekdays in the absence of disease progression or unacceptable toxicity. \> \> Carboplatin: Chemotherapy \> \> Cisplatin: Chemotherapy \> \> Etoposide: Chemotherapy \> \> Paclitaxel: Chemotherapy \> \> Pemetrexed: Chemotherapy \> \> Proton Beam Radiation Therapy: Undergo PBT \> \> Quality-of-Life Assessment: Ancillary studies \> \> Questionnaire Administration: Ancillary studies
Proportion of Participants With Distant Metastasis	0.29 proportion of participants Interval 0.08 to 0.64	0.1 proportion of participants Interval 0.018 to 0.4

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 5 years

Measured using the single item Linear Analogue Self-Assessment scale. Descriptive statistics by dose level at each time point will include means, standard deviations, medians, and ranges for each scale. Descriptive graphical techniques will include mean plots by dose over time for each scale. Mixed models will be used to compare each scale across dose levels at each post-baseline time point while adjusting for the baseline value of scale. Will graphically explore patterns of missing data and will employ pattern mixture models for longitudinal analyses. The lowest number measuring worst and higher number measuring best outcome.

Outcome measures

Outcome data not reported

Adverse Events

Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT)

Serious events: 5 serious events

Other events: 10 other events

Deaths: 6 deaths

Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT)

Serious events: 5 serious events

Other events: 7 other events

Deaths: 5 deaths

Serious adverse events

Serious adverse events
Measure	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 participants at risk Questionnaire Administration: Ancillary studies	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=9 participants at risk Questionnaire Administration: Ancillary studies
General disorders Death NOS	50.0% 5/10 • Number of events 5 • Up to 5 years	55.6% 5/9 • Number of events 5 • Up to 5 years
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.00% 0/10 • Up to 5 years	11.1% 1/9 • Number of events 1 • Up to 5 years

Other adverse events

Other adverse events
Measure	Arm A (Platinum Doublet Chemotherapy, Lower Dose PBT) n=10 participants at risk Questionnaire Administration: Ancillary studies	Arm C (Platinum Doublet Chemotherapy, Higher Dose PBT) n=9 participants at risk Questionnaire Administration: Ancillary studies
Gastrointestinal disorders Esophageal pain	10.0% 1/10 • Number of events 1 • Up to 5 years	0.00% 0/9 • Up to 5 years
Gastrointestinal disorders Esophagitis	70.0% 7/10 • Number of events 15 • Up to 5 years	77.8% 7/9 • Number of events 11 • Up to 5 years
Gastrointestinal disorders Nausea	40.0% 4/10 • Number of events 5 • Up to 5 years	44.4% 4/9 • Number of events 4 • Up to 5 years
Gastrointestinal disorders Vomiting	10.0% 1/10 • Number of events 1 • Up to 5 years	0.00% 0/9 • Up to 5 years
General disorders Fatigue	80.0% 8/10 • Number of events 16 • Up to 5 years	66.7% 6/9 • Number of events 9 • Up to 5 years
General disorders Pain	20.0% 2/10 • Number of events 2 • Up to 5 years	22.2% 2/9 • Number of events 3 • Up to 5 years
Injury, poisoning and procedural complications Dermatitis radiation	60.0% 6/10 • Number of events 6 • Up to 5 years	77.8% 7/9 • Number of events 7 • Up to 5 years
Investigations Weight loss	30.0% 3/10 • Number of events 3 • Up to 5 years	22.2% 2/9 • Number of events 2 • Up to 5 years
Metabolism and nutrition disorders Anorexia	10.0% 1/10 • Number of events 1 • Up to 5 years	33.3% 3/9 • Number of events 3 • Up to 5 years
Metabolism and nutrition disorders Dehydration	50.0% 5/10 • Number of events 7 • Up to 5 years	55.6% 5/9 • Number of events 5 • Up to 5 years
Respiratory, thoracic and mediastinal disorders Cough	70.0% 7/10 • Number of events 16 • Up to 5 years	77.8% 7/9 • Number of events 10 • Up to 5 years
Respiratory, thoracic and mediastinal disorders Dyspnea	80.0% 8/10 • Number of events 18 • Up to 5 years	55.6% 5/9 • Number of events 7 • Up to 5 years
Respiratory, thoracic and mediastinal disorders Pneumonitis	40.0% 4/10 • Number of events 5 • Up to 5 years	22.2% 2/9 • Number of events 2 • Up to 5 years
Respiratory, thoracic and mediastinal disorders Productive cough	10.0% 1/10 • Number of events 2 • Up to 5 years	0.00% 0/9 • Up to 5 years
Cardiac disorders Myocardial infarction	0.00% 0/10 • Up to 5 years	11.1% 1/9 • Number of events 1 • Up to 5 years
Gastrointestinal disorders Constipation	60.0% 6/10 • Number of events 8 • Up to 5 years	22.2% 2/9 • Number of events 3 • Up to 5 years
Gastrointestinal disorders Diarrhea	10.0% 1/10 • Number of events 1 • Up to 5 years	11.1% 1/9 • Number of events 1 • Up to 5 years
Gastrointestinal disorders Dysphagia	90.0% 9/10 • Number of events 18 • Up to 5 years	44.4% 4/9 • Number of events 4 • Up to 5 years

Additional Information

Dr. Steven E. Schild

Mayo Clinic

Phone: 480-342-4800

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place